Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Characterization of Joint Disease in Women with Hemophilia: The Carriers Ultrasound Project (CUP) Study

Rachel S. Kronenfeld, Kelli Fraga, Maria D'Almeida Bastos, Amina Rafique, Christine Kempton, Joanna Davis, Fernando F Corrales-Medina

Blood (2023) 142 (Supplement 1): 29.

https://doi.org/10.1182/blood-2023-172662

Published: 2023

Journal Articles

Validation of Isolation Methodology and Endogenous Control Selection for qRT-PCR Assessment of Microrna Expression in Serum and Urine Exosomes

Rachel E Crossland, PhD, Jean Norden, Louis Bibby, BSc, Joanna Davis, BSc, Anne M Dickinson, PhD

Blood (2014) 124 (21): 5793.

https://doi.org/10.1182/blood.V124.21.5793.5793

Published: 2014

Journal Articles

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

Tom E. Howard, MD, PhD, Deepa K. Machiah, BS, Kevin R. Viel, PhD, Cynthia Channel, BS, Afshin Ameri, MD, Rathi V. Iyer, MD, Ray G. Watts, MD, Charles Lutcher, MD, Joanna Davis, MD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2005) 106 (11): 3207.

https://doi.org/10.1182/blood.V106.11.3207.3207

Published: 2005

Journal Articles

African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?.

Tom Howard, M.D., Ph.D., Deepa M. Machiah, Ph.D., Thuy T. Tran, Kevin R. Viel, B.S., Cynthia Channell, B.S., Jose Manuel Soria, Ph.D., Afshin Ameri, M.D., Rathi V. Iyer, M.D., Cara Brown, B.S., R.N., Christopher Doering, Ph.D., Laura Almasy, Ph.D., Ray Watts, M.D., Joanna Davis, M.D., Thomas C. Abshire, M.D.

Blood (2004) 104 (11): 384.

https://doi.org/10.1182/blood.V104.11.384.384

Published: 2004

NARROW

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Characterization of Joint Disease in Women with Hemophilia: The Carriers Ultrasound Project (CUP) Study

Validation of Isolation Methodology and Endogenous Control Selection for qRT-PCR Assessment of Microrna Expression in Serum and Urine Exosomes

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?.

Email alerts

ASH Publications

American Society of Hematology

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Characterization of Joint Disease in Women with Hemophilia: The Carriers Ultrasound Project (CUP) Study

Validation of Isolation Methodology and Endogenous Control Selection for qRT-PCR Assessment of Microrna Expression in Serum and Urine Exosomes

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.

African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only